Beta: Sign in
Shares outstandingAs of 2025-12-31 · filed common shares: 61.97M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 0.01%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 6.78%
Short ratioDays to cover, as published by FINRA: 9.50
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 41.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 53.30%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Loading evidence for ASND

Avg volume (3 months)

Profitability

Gross marginFY Dec 25: 86.82%
Operating marginFY Dec 25: -18.92%
Net margin: —
EBITDA marginFY Dec 25: -14.82%
Return on equity: —
Return on assetsNet income (FY Dec 25) ÷ average total assets: -18.37%

Growth

Revenue growth (annual YoY): 98.03%
Revenue growth (latest qtr YoY): 269.40%
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales: Sign in
Price / operating cash flow: Sign in
P/FCF: Sign in
EV / revenue: Sign in
EV / EBITDA: Sign in
EPSDiluted, FY Dec 25: -3.76
EPS (fwd): Sign in

Financial health

Cash & equivalentsas of Dec 25: EUR 616.04M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: EUR 814.64M
Debt / equityas of Dec 25: -500.33%
Current ratioas of Dec 25: 1.04
Quick ratio: —
Operating cash flowFY Dec 25: EUR 53.89M
Free cash flow (nine months)Nine months: 2024-01-01 to 2024-09-30 · Not annualized: -EUR 220.02M
TTM revenue / diluted shareDiluted, FY Dec 25: 11.88

ASND stock Statistics — Ascendis Pharma A/S filings, insiders & smart money · Instaport